OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+75.06%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$495M
AUM Growth
+$495M
(+31%)
Cap. Flow
+$19.1M
Cap. Flow
% of AUM
3.86%
Top 10 Holdings %
Top 10 Hldgs %
52.26%
Holding
59
New
16
Increased
13
Reduced
8
Closed
11
Top Buys
| 1 |
Celldex Therapeutics
CLDX
|
$13.9M |
| 2 |
Fortress Biotech
FBIO
|
$10.3M |
| 3 |
Kiniksa Pharmaceuticals
KNSA
|
$8.78M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$8.36M |
| 5 |
Ocular Therapeutix
OCUL
|
$7.18M |
Top Sells
| 1 |
FTSV
Forty Seven, Inc. Common Stock
FTSV
|
$36.8M |
| 2 |
APTO
Aptose Biosciences, Inc.
APTO
|
$5.63M |
| 3 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$4.83M |
| 4 |
Zymeworks
ZYME
|
$4.72M |
| 5 |
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
|
$4.66M |
Sector Composition
| 1 | Healthcare | 91.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Protara Therapeutics
TARA
$120M
| $64.8M | 13.08% | 2,208,472 | – | – |
|
|
2
Ocular Therapeutix
OCUL
$2.12B
| $49.8M | 10.07% | 5,984,200 +861,700 | +17% | +$7.18M |
|
3
Neurogene
NGNE
$264M
| $23.2M | 4.69% | 1,400,000 | – | – |
|
|
CCXI
4
DELISTED
ChemoCentryx, Inc.
CCXI
| $20.8M | 4.2% | 361,600 | – | – |
|
5
Eton Pharmaceutcials
ETON
$464M
| $19.8M | 4.01% | 3,640,000 | – | – |
|
|
APTO
6
DELISTED
Aptose Biosciences, Inc.
APTO
| $19.8M | 3.99% | 3,130,000 -892,000 | -22% | -$5.63M |
|
7
Codexis
CDXS
$246M
| $16.1M | 3.25% | 1,400,000 | – | – |
|
8
Stereotaxis
STXS
$261M
| $15.7M | 3.16% | 3,511,500 -350,000 | -9% | -$1.56M |
|
|
EIDX
9
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $14.6M | 2.96% | 315,550 | – | – |
|
10
Harrow
HROW
$1.44B
| $14.1M | 2.85% | 2,710,000 +210,000 | +8% | +$1.09M |
|
|
MYOV
11
DELISTED
Myovant Sciences Ltd.
MYOV
| $14.1M | 2.84% | 682,500 +26,500 | +4% | +$546K |
|
12
MacroGenics
MGNX
$112M
| $14M | 2.83% | 501,000 +78,700 | +19% | +$2.2M |
|
|
13
Celldex Therapeutics
CLDX
$1.47B
| $13.9M | 2.81% | +1,071,000 | New | +$13.9M |
|
|
DCPH
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $13.1M | 2.64% | 222,000 | – | – |
|
|
ATXI
15
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
| $11.1M | 2.25% | 1,035,000 | – | – |
|
|
ODT
16
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $10.6M | 2.14% | 250,000 -110,000 | -31% | -$4.66M |
|
|
17
Fortress Biotech
FBIO
$76.8M
| $10.3M | 2.07% | +3,830,000 | New | +$10.3M |
|
18
TG Therapeutics
TGTX
$4.65B
| $8.9M | 1.8% | 456,600 -36,400 | -7% | -$709K |
|
|
19
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $8.78M | 1.77% | +344,500 | New | +$8.78M |
|
20
Avalo Therapeutics
AVTX
$122M
| $8.77M | 1.77% | 3,372,500 +1,169,400 | +53% | +$3.04M |
|
21
uniQure
QURE
$896M
| $8.55M | 1.73% | 270,400 +60,400 | +29% | +$1.91M |
|
|
BHVN
22
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $8.36M | 1.69% | +114,350 | New | +$8.36M |
|
23
Xoma
XOMA
$392M
| $8.21M | 1.66% | 415,380 +28,380 | +7% | +$561K |
|
24
Crinetics Pharmaceuticals
CRNX
$2.92B
| $7.63M | 1.54% | 435,200 +66,450 | +18% | +$1.16M |
|
25
Cytokinetics
CYTK
$4.23B
| $7.14M | 1.44% | +303,050 | New | +$7.14M |
|